Company Encyclopedia
View More
name
Avalo Therapeutics
AVTX.US
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc.
1.935 T
AVTX.USMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking242/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-177.05%E
    • Profit Margin-52019.79%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-76.59%E
    • Net Profit YoY-1125.58%E
    • Total Assets YoY27.06%A
    • Net Assets YoY302.69%A
  • Cash ScoreD
    • Cash Flow Margin-0.19%D
    • OCF YoY-76.59%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio26.82%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

    Top Wall Street analysts initiated coverage on several stocks with bullish ratings. Avalo Therapeutics received an Outperform rating with a $39 target, Lexeo Therapeutics a Strong Buy with a $25 target, Valvoline a Buy with a $42 target, Serve Robotics an Outperform with a $20 target, and Sotera Health an Outperform rating. Analysts are optimistic about these stocks.

    benzinga_article·
    US
    VVV
    -0.76%
    US
    SERV
    -5.23%
    US
    SHC
    0.00%
    benzinga_article·
    US
    VVV
    -0.76%
    US
    SERV
    -5.23%
    US
    SHC
    0.00%

    Avalo Therapeutics Director Makes Significant Stock Sale!

    Avalo Therapeutics Director Jonathan Goldman sold 11,367 shares for $162,876. The company completed patient enrollment for its Phase 2 LOTUS trial of AVTX-009, despite a net loss of $30.6 million. Avalo maintains a strong cash position for the next year. Spark's AI Analyst rates AVTX as Neutral due to financial challenges, despite some positive technical indicators. Avalo's market cap is $274M, with a YTD price performance of 79.24% and a technical sentiment signal of Sell.

    Tip Ranks·
    US
    AVTX
    -2.86%
    Tip Ranks·
    US
    AVTX
    -2.86%

    Nektar Therapeutics Reports Q3 2025 Financial Results

    Nektar Therapeutics (NKTR) reported its Q3 2025 financial results, revealing a revenue drop to $11.8 million from $24.1 million in Q3 2024, mainly due to the sale of its Huntsville manufacturing facility. The net loss improved slightly to $35.5 million from $37.1 million year-over-year. Operating costs decreased to $43.5 million, attributed to reduced R&D expenses. The company raised capital through stock offerings and received FDA Fast Track designation for its lead product, rezpegaldesleukin, targeting severe alopecia areata. Nektar aims to advance its pipeline and sustain operations into Q2 2027.

    Tip Ranks·
    US
    NKTR
    +1.25%
    Tip Ranks·
    US
    NKTR
    +1.25%

    Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete

    Avalo Therapeutics reported a Q3 net loss of $30.63 million, missing analyst expectations of $18.75 million. Operating expenses increased due to costs from the Phase 2 LOTUS trial, which has completed enrollment with data expected by mid-2026. Avalo anticipates cash reserves to sustain operations until 2028. The average analyst rating for Avalo shares is "buy," with a median 12-month price target of $35.00, representing a 53% upside from its recent closing price of $16.45.

    Reuters·
    US
    AVTX
    -2.86%
    Reuters·
    US
    AVTX
    -2.86%

    Avalo Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AVTX
    -2.86%
    LB filings·
    US
    AVTX
    -2.86%
    © 2025 Longbridge｜Disclaimer